| Product sales | 96.7M |
| Contracts and grants | 31.5M |
| Total revenues | 142.91M |
| Cost of product sales | 39.56M |
| Research and development | 27.19M |
| Selling, general and administrative | 40.69M |
| Income (loss) from operations | 35.48M |
| Interest income | 358K |
| Interest expense | -2.05M |
| Other income (expense), net | -234K |
| Total other income (expense) | -1.93M |
| Income (loss) before provision for (benefit from) income taxes | 33.55M |
| Provision for (benefit from) income taxes | 13.17M |
| Net income (loss) | |
| Net loss attributable to noncontrolling interests | |
| Net income (loss) attributable to Emergent BioSolutions Inc. | 21.34M |
| Earnings per share - basic | 0.52 |
| Earnings per share - diluted | 0.45 |
| Weighted-average number of shares - basic | 40.47M |
| Weighted-average number of shares - diluted | 49.44M |